3 Healthcare Stocks in Focus; AMGN, BIIB, AFFY

Amgen Inc. ( NASDAQ: AMGN ), on Monday, announced its fourth-quarter financial results. The company reported fourth-quarter adjusted earnings per share of $1.17, up 11% over the same period in 2009. For full year 2010, the company reported adjusted earnings per share of $5.21, up 6%. Amgen also announced that for 2011 it expects the total revenue to be in the range of $15.1-$15.5 billion and adjusted EPS to be in the range of $5.00-$5.20. Amgen shares have a 52-week range of $50.26-$61.26. In the last one year, the stock gained 3.345%. Thousand Oaks, California-based Amgen is an independent biotechnology medicines company, engaged in the discovery, development, manufacturing and marketing of medicines for grievous illnesses. Biogen Idec Inc. ( NASDAQ: BIIB ), last week, announced the issuance of negative opinion recommending against approval of its FAMPYRA by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Biogen said that it plans to appeal this opinion and request a re-examination of the decision by the CHMP. Biogen shares have a 52-week range of $45.96-$68.99. The stock gained 26.47% in the last one year. Cambridge, Massachusetts-based Biogen is a biotechnology company. The company's products include AVONEX, RITUXAN, TYSABRI and FUMADERM. Affymax Inc. ( NASDAQ: AFFY ), earlier this month, announced the appointment of John Orwin as its new CEO and member of Board of Directors, effective February 1, 2011. Orwin will replace Arlene Morris as the company's CEO. Affymax shares have a 52-week range of $4.90-$26.20. The stock fell 66.98% in the last one year. Affymax is a biopharmaceutical company based in Palo Alto, California and engaged in the development of drugs to improve the treatment of serious and often life-threatening conditions. This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell any stock mentioned in this report at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live